A5063556245- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cardiac electrophysiology and arrhythmias
- Venous Thromboembolism Diagnosis and Management
- Neutropenia and Cancer Infections
- COVID-19 and healthcare impacts
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Lung Cancer Research Studies
- Acute Ischemic Stroke Management
- Cardiac Valve Diseases and Treatments
- Cardiovascular Syncope and Autonomic Disorders
- Inflammatory Bowel Disease
- Cardiac Arrest and Resuscitation
- Cardiovascular Health and Risk Factors
- Neuroendocrine Tumor Research Advances
- Mechanical Circulatory Support Devices
- Respiratory Support and Mechanisms
- Cytomegalovirus and herpesvirus research
- Infective Endocarditis Diagnosis and Management
- Cancer Immunotherapy and Biomarkers
- Cardiac, Anesthesia and Surgical Outcomes
University of Pittsburgh Medical Center
2013-2024
MedStar Georgetown University Hospital
2024
Stony Brook University Hospital
2024
The University of Kansas Cancer Center
2020-2023
University of Kansas Medical Center
2019-2023
University of Kansas
2013-2023
University Medical Center
2020-2022
University Hospital and Clinics
2020-2022
Shawnee Mission Medical Center
2020-2021
Shadyside Hospital
2014-2018
Atrial fibrillation ablation has made tremendous progress with respect to innovation, efficacy, and safety. However, limited data exist regarding the burden trends in adverse outcomes arising from this procedure. The aim of our study was examine frequency events attributable atrial (AF) influence operator hospital volume on outcomes.With use Nationwide Inpatient Sample, we identified AF patients treated catheter ablation. We investigated common complications including cardiac perforation...
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The associated morbidity and mortality make AF a major public health burden. Hospitalizations account for majority of economic cost burden with AF. main objective this study to examine trends AF-related hospitalizations in United States compare patient characteristics, outcomes, comorbid diagnoses.With use Nationwide Inpatient Sample from 2000 through 2010, we identified using International Classification Diseases, 9th...
BACKGROUND Extrapulmonary neuroendocrine carcinomas (NECs) are poorly studied and managed similar to lung NECs, which may not account for differences between the 2 groups of tumors as well heterogeneity within extrapulmonary NEC. METHODS Data from Surveillance, Epidemiology, End Results program 1973 2012 were used estimate relative percentages NECs subgroups epidemiological patterns at these sites, median 5‐year overall survival rates. RESULTS Of 162,983 NEC cases, 14,732 extrapulmonary;...
The relationship between operator or institutional volume and outcomes among patients undergoing percutaneous coronary interventions (PCI) is unclear.Cross-sectional study based on the Healthcare Cost Utilization Project's Nationwide Inpatient Sample 2005 to 2009. Subjects were identified by International Classification of Diseases, 9(th) Revision, Clinical Modification procedure code, 36.06 36.07. Annual volumes calculated using unique identification numbers then divided into quartiles....
Abstract Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim the NeoSTOP multisite randomized phase II trial was assess efficacy anthracycline-free anthracycline-containing neoadjuvant regimens. Patients Methods: aged ≥18 years with stage I–III TNBC were (1:1) receive either paclitaxel (P) weekly × 12 AUC6 every 21 days 4 followed...
8504 Background: In unselected patients (pts) with extensive-stage small cell lung cancer (ES-SCLC), the addition of immune checkpoint inhibitors (ICI) to chemotherapy resulted in a modest improvement OS. retrospective analysis study veliparib (PARP inhibitor [PARPi]) and temozolomide SCLC, Schlafen-11 (SLFN11) predicted PFS OS benefit for PARPi. We evaluated whether PARPi (talazoparib) standard-of-care maintenance ICI (atezolizumab) following frontline chemoimmunotherapy improved outcomes...
Safety data on percutaneous left atrial appendage closure arises from centers with considerable expertise in the procedure or clinical trial, which might not be reproducible practice. We sought to estimate frequency and predictors of adverse outcomes costs US.The were obtained Nationwide Inpatient Sample years 2006 2010. The is largest all-payer inpatient set US. Complications calculated using patient safety indicators International Classification Diseases-Ninth Revision, Clinical...
Contemporary data regarding percutaneous closure of atrial septal defect/patent foramen ovale (ASD/PFO) are lacking. We evaluated the current trends in utilization ASD/PFO adults and investigated effect annual hospital volume on in-hospital outcomes.We queried Nationwide Inpatient Sample between years 2001 2010 using International Classification Diseases (ICD-9-CM) procedure code for with device. Hierarchical mixed effects models were generated to identify independent multivariate predictors...
Prior studies have shown that outcomes of hematopoietic stem cell transplantation (HSCT) in human immunodeficiency virus (HIV)-positive patients been similar to HIV-negative since effective implementation highly active antiretroviral therapy by 1998, but they are limited small sample size or noninclusion recent data.We queried National Inpatient Sample, a large inpatient data set the United States, from 1998 2012 for HSCT, using International Classification Diseases, Ninth Revision, Clinical...